Half of patients on the weight loss drug semaglutide who do not have diabetes stop taking it within a year.

This is the discovery of a population-wide study that looked into adults who started taking the drug in Denmark.

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists (GLP-1RAs), which, outside of potential side effects, are proving remarkably effective at helping people lose weight.

However, the new research being presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna (15–19 Sept) sheds light on high rates of early discontinuation and reasons contributing to this.

"This level of drop off is concerning because these medications aren't meant to be a temporary quick fix," study author and epidemiologist profes

See Full Page